MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Academic group to receive a total of $22 million for the trialLA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova ...
WPBF6d
'Walk to Defeat ALS': Amyotrophic Lateral Sclerosis Awareness Day
28 as ALS Awareness Day.Amyotrophic lateral sclerosis is a disease that attacks the nervous system, affecting nerve cells in the brain and spinal cord.Morning Traffic anchor Yasmine Julmisse ...
BioWorld1d
Reverse engineering opens path for precisely targeted gene therapies for ALS and FTD
Researchers in the U.K. have succeeded in reverse engineering the defective cryptic splicing that drives amyotrophic lateral ...
Rozebalamin(R) For Injection 25 Mg (Mecobalamin) Approved In Japan For Amyotrophic Lateral Sclerosis
About Rozebalamin (generic name: mecobalamin, development code: E0302) ...
ALS News Today1d
Immune proteins activation at ALS diagnosis linked to progression
Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...
Business Insider5d
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...
New Atlas9d
Synapse-restoring pill set for human trials as novel schizophrenia treatment
Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic ...
Nyberg: ALS United Connecticut provides resources to people, families impacted
Amyotrophic lateral sclerosis, better known as ALS, is a nervous system disease that affects nerve cells in the brain and ...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has ...
ALS News Today10d
Scientists validate blood test that may speed up diagnosis of ALS
A group of eight molecules in the blood can be used as a biomarker to distinguish ALS from other neurodegenerative conditions ...
Annual Walk to Defeat ALS raises money and awareness
The community will gather in Jordan Valley Park on Saturday to walk in the name of an incurable disease. The ALS Association will be having its annual Walk to Defeat ALS fundraiser to raise money and ...